Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy has been successful in the treatment of advanced estrogen receptor–positive (ER+) breast cancer. Although there has been overall progress in the treatment of cancer, drug resistance is an emerging cause for breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhen, Zou, Wei, Zhang, Ji, Zhang, Yunjiao, Xu, Qi, Li, Siyuan, Chen, Ceshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751736/
https://www.ncbi.nlm.nih.gov/pubmed/33364954
http://dx.doi.org/10.3389/fphar.2020.580251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751736/
https://www.ncbi.nlm.nih.gov/pubmed/33364954
http://dx.doi.org/10.3389/fphar.2020.580251

Ejemplares similares